Search PubMed⌕ Search

Biomedical subjects

N Panza

Publications and source records attributed to N Panza.

71 records · Page 4Linked to original sources
PubMed1983

Study of the pituitary-thyroid axis in euthyroid goiter after partial thyroidectomy.

The aim of this study was to investigate the time involved after hemithyroidectomy in reaching a new steady state in thyroid function and the relationship between thyroid hormones, basal TSH levels and TSH response to TRH. The investigations were performed on 35 patients 12-18 months after partial thyroidectomy in the first investigation and after 24-30 months in the second investigation. Tests included T4, T3, FT4, FT3 serum levels, basal serum TSH and TSH response to TRH. None of the patients received thyroid replacement and 38 healthy subjects of comparable age and sex were used as controls. We conclude that: i) the time involved in reaching a new steady state of thyroid function in hemithyroidectomized patients is variable and may take a long time; ii) TSH response to TRH returns to the normal range later than thyroid hormone and basal TSH levels.

Adult↗
PubMed1982

Strong association between an HLA-DR antigen and thyroid carcinoma.

A group of 20 patients affected with thyroid carcinoma, all from Southern Italy, was typed for HLA-A, -B, -C and -DR antigens. Sixteen of them (80%) typed for DR1, while in the control group (120 unrelated healthy individuals from the same region) only 22 (18.3%) shared the same antigen (chi 2 = 32.96). The data indicate a highly significant association between the HLA-DR1 gene and the thyroid carcinoma.

Adenocarcinoma↗
PubMed1979

DNA and oestradiol receptor distribution in human breast cancer.

The content of DNA and oestradiol receptors was measured in two different samples taken from the same tumoral mass of 33 primary infiltrating ductal carcinomas. The results were related to the total cytoplasmic protein and to the DNA of the tissue. The results showed that variations of both DNA and oestradiol receptors are frequent and often significant. The reliability of analyses carried out on a single biopsy is discussed.

Breast Neoplasms↗
PubMed1979

[Estrogen receptors in rabbit thymus].

The estrogen receptors presence or absence in the thymus gland represents the basic element to assert or to exclude any estrogenic action in the thymus. Now we have measured the presence of cytoplasmatic estrogen receptors in the female rabbits thymus, using some methods (sucrose gradient, protamine sulphate, dextran-coated charcoal). Finally, we have investigated, using the sucrose gradient assay, the nuclear ER presence in 1000g thymic pellet. The results exclude high levels of estrogen-binding proteins while don't suggest their total absence in the female rabbit thymus.

Animals↗
PubMedDate not supplied

Second-line chemotherapy with paclitaxel, cisplatin and gemcitabine in pre-treated sensitive cisplatin-based patients with advanced non-small cell lung cancer.

BACKGROUND: To investigate the safety and effectiveness of the combination of paclitaxel, cisplatin and gemcitabine as second-line in patients with advanced non-small cell lung cancer (NSCLC) sensitive to first-line cisplatin-based chemotherapy. PATIENTS AND METHODS: From June 1997 to December 1998, 26 patients with stage IIIB or IV NSCLC received paclitaxel 125 mg/m2, as a one-hour infusion, followed by cisplatin 50 mg/m2 and gemcitabine 1000 mg/m2, intravenously, on day 1 and 8, every 3 weeks. Twenty-three patients were male; the median age was 59 years (range 44-70); The Eastern Cooperative Oncology Group performance status was 0 to 1 in 88% of patients; 16 patients had stage IV disease and 7 patients had 3 or more sites of disease. The predominant histology was adenocarcinoma in 14 patients. Prior treatment involved cisplatin plus vinorelbine in 14 patients and cisplatin plus mitomycin C plus vindesine in 12 cases. RESULTS: Seven (27%; exact 95% confidence limits: 11.6-47.8%) patients achieved a partial response to treatment whilst 7 (27%) had stable disease. The median duration of response was 22 weeks (range, 18 to 34 weeks). The median overall survival was 24 weeks (range, 8 to 36 weeks). The main toxicities were: grade 3-4 neutropenia in 9 (34%) patients; grade 2-3 peripheral neuropathy in 10 (38%); and grade 2-3 asthenia in 15 (57%) cases. CONCLUSION: The paclitaxel, cisplatin and gemcitabine combination is active as a second-line regimen in patients with advanced NSCLC, but with mild toxicity. It seems suitable for patients with advanced NSCLC as a first-line treatment.

Adenocarcinoma↗
PubMedDate not supplied

Evaluation of TAG-72 as a serum marker in ovarian and breast carcinoma.

Tumor Associated Glycoprotein 72 (TAG-72) is common to most epithelial tumors. In this study serum levels of TAG-72 were measured in 36 healthy female subjects, in 94 patients with breast cancer, and in 43 others with epithelial ovarian cancer. More particularly, 27 out of the 94 patients with breast cancer had early disease (Stage I-I; or T 0-2b; N 0-1b; M 0), while the remaining 67 had advanced disease (Stage III-IV; or T 0-4; N 0-3; M 0-1). All the 43 subjects with ovarian cancer were at stage III-IV (FIGO Classification), 12 of whom had minimal disease (lesions less than 2 cm) and the other 31 had bulky disease. 3.5 U/ml being the highest value found in the control group, we arbitrarily assumed 3.85 U/ml (mean +/- 3 SD) as the cut-off limit in this preliminary study. Among the patients with breast cancer, 17 out of the 67 subjects with advanced disease (25.3%) and 1 out of the 27 others with early disease (3.7%) exceeded the TAG-72 cut-off limit. Among the patients with ovarian cancer, 2 out of the 12 subjects with minimal disease (16.7%) and 22 out of the others 31 with bulky disease (70.9%) had TAG-72 levels above cut-off limit. High TAG-72 levels were found in all the histotypes of ovarian cancer including the mucinous type. Preliminary data seem to indicate that in ovarian cancer variations in serum levels of TAG-72 are in agreement with the trend of the disease.(ABSTRACT TRUNCATED AT 250 WORDS)

Antigens, Neoplasm↗